SynthesisCancer medicine2019
Age at menarche and epithelial ovarian cancer risk: A meta-analysis and Mendelian randomization study.
Synthesis in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Risk factors of ovarian cancer: a systematic review and meta-analysis of Mendelian randomiation studies.Journal of public health (Oxford, England) · 2026Pooled it
- Systematic review of Mendelian randomization studies on risk of cancer.BMC medicine · 2022Pooled it
- Age at menarche and epithelial ovarian cancer risk: A meta-analysis and Mendelian randomization study.Cancer medicine · 2019Pooled it
- Global Patterns and Temporal Trends in Ovarian and Uterine Cancer Mortality Attributable to High Body-Mass Index, 1990-2023.Cancers · 2026Article
- Association between childhood adiposity and gynecologic cancers: a mendelian randomization analysis.BMC women's health · 2025Article
- Maternal pre-pregnancy overweight/obesity, in-utero exposure to toxic heavy metals, and offspring age at peak height velocity: A prospective birth cohort study.Environmental research · 2025Article
- Global epidemiology of epithelial ovarian cancer.Nature reviews. Clinical oncology · 2024Review
- The Associations and Causal Relationships of Ovarian Cancer - Construction of a Prediction Model.International journal of women's health · 2024Article
- The causal effects of genetically determined immune cells on gynecologic malignancies: a Mendelian randomization study.Frontiers in oncology · 2024Article
- Stratifying the risk of ovarian cancer incidence by histologic subtypes in the Korean Epithelial Ovarian Cancer Study (Ko-EVE).Cancer medicine · 2023Article
- Genetic causal relationship between age at menarche and benign oesophageal neoplasia identified by a Mendelian randomization study.Frontiers in endocrinology · 2023Article
- Incessant ovulation: a review of its importance in predicting cancer risk.Frontiers in oncology · 2023Article
- Genetically predicted serum testosterone and risk of gynecological disorders: a Mendelian randomization study.Frontiers in endocrinology · 2023Article
- Serum Estradiol and 20 Site-Specific Cancers in Women: Mendelian Randomization Study.The Journal of clinical endocrinology and metabolism · 2022Article
- Review of Mendelian Randomization Studies on Ovarian Cancer.Frontiers in oncology · 2021Review
- MicroRNA-145-5p regulates the proliferation of epithelial ovarian cancer cells via targeting SMAD4.Journal of ovarian research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age at menarche (AAM) was found to be associated with ovarian cancer risk in previous observational studies. However, the causality of this association remains unclear. Here, after systematic meta-analyses, we performed two-sample Mendelian randomization (MR) analyses to evaluate the causal effect of AAM in epithelial ovarian cancer (EOC) etiology. We performed meta-analyses including 11 410 cases and 1 163 117 noncases to quantitatively evaluate the association between AAM and ovarian cancer risk. In MR analyses, we used 25 single nucleotide polymorphisms (SNPs) associated with AAM for Chinese and 390 SNPs for Europeans as instrumental variables. MR estimates were calculated using inverse-variance weighted methods from 1044 cases and 1172 controls in a Chinese genome-wide association study and validated by the Ovarian Cancer Association Consortium and Consortium of Investigators of Modifiers of BRCA1/2 studies with 29 396 cases and 68 502 controls of European ancestry. In meta-analyses, we observed an inverse association (odds ratio [OR] = 0.96, 95% confidence interval [CI] = 0.93 to 1.00, P = 0.036) between per year older AAM and ovarian cancer risk in case-control studies, but no association was observed in cohort studies. In MR analyses, the OR of EOC risk per year increase in AAM was 0.81 (95% CI = 0.67 to 0.97, P = 0.026) in Chinese and 0.94 (95% CI = 0.90 to 0.98, P = 0.003) in Europeans, respectively. Our study supports a causal association between AAM and EOC risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.